Enlivex Therapeutics Announces Cost‑Reduction Plan and Refocuses on Phase 2b Allocetra Trial
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced on 19 October 2026 a comprehensive cost‑reduction plan designed to concentrate the company’s resources on its Phase 2b trial of Allocetra for age‑related primary moderate‑to‑severe knee osteoarthritis.
The plan, effective immediately, involves the following measures:
- Workforce Reduction – Approximately 60 % of the company’s employees will be laid off.
- Salary Reductions – Management salaries will be cut by 20 %, while the Chief Executive Officer’s salary will be reduced by 40 %.
- Research & Development Consolidation – All research and development activities unrelated to the Phase 2b trial will be discontinued.
Enlivex expects the restructuring to substantially reduce cash burn, with preliminary projections indicating a six‑month turnaround for topline trial data by mid‑2027.
Focus on Allocetra Phase 2b Trial
The Phase 2b trial evaluates patients aged 64 years and older with moderate‑to‑severe, age‑related symptomatic primary knee osteoarthritis. This patient population received a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration in July 2026.
A completed Phase 1/2a study demonstrated statistically significant improvements in pain and function versus placebo at both three‑month and six‑month follow‑ups in the responder population, with a favorable safety profile.
Market Context
As of 18 October 2026, Enlivex’s share price stood at US $0.207, with a market capitalization of approximately $4.08 million. The company’s 52‑week high was $27.15 on 23 November 2025, while its 52‑week low was $0.193 on 18 October 2026.
Enlivex’s decision to streamline operations and concentrate on a single, FDA‑designated trial reflects a strategic shift aimed at optimizing limited resources and accelerating the development timeline for its flagship product.
